Degenerative Neurological and Neuromuscular Disease

Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes

Andreas-Antonios Roussakis
Paola Piccini
Marios Politis
Centre for Neuroinflammation and Neurodegeneration, Imperial College London, London, United Kingdom

Correspondence: Marios Politis
Imperial College London,
Hammersmith Hospital Campus,
Centre for Neuroinflammation and Neurodegeneration,
Neurology Imaging Unit,
1st floor, B Block, Du Cane Road, W12 0NN, London, UK
Tel +44 20 8383 3751
Fax +44 20 3313 4320
Email marios.politis@imperial.ac.uk

Abstract: The diagnosis of movement disorders including Parkinsonian syndromes and essential tremor is mainly clinical. The most common diagnostic errors for Parkinson’s disease include misdiagnoses such as Parkinson plus syndromes and cases of essential tremor. In this article, we discuss the clinical utility of DaTscan™ (123I-Ioflupane injection) and its diagnostic value in Parkinson’s disease and the other Parkinsonian syndromes. Single photon emission computed tomography with 123I-Ioflupane can be useful to assist in the diagnosis of uncertain cases of Parkinsonism. An accurate diagnosis can aid clinicians in making correct decisions that are related to the overall management and treatment of Parkinson’s disease, avoiding common therapeutic errors.

Keywords: DaTscan, SPECT, 123I-Ioflupane, 123I-β-FP-CIT, Parkinsonism

An introduction to diagnostic issues in Parkinson’s disease

Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by motor and nonmotor symptoms. PD is the second most common neurodegenerative disorder after dementia affecting approximately 1%–2% of the general population. The cardinal pathological feature of PD is the depletion of dopamine in the substantia nigra pars compacta.

The diagnosis of PD is essentially clinical and is based on identifying clinical characteristics related to striatal dopamine depletion, which typically manifest as motor signs and symptoms (tremor, bradykinesia, and rigidity). In fact, a good response to dopaminergic medication is consistent with a typical case of idiopathic PD. However, a typical clinical image may not be fully manifested in early PD; nonmotor symptoms, such as sleep disorders and hyposmia may precede motor symptoms while depression, dementia, and fatigue can dominate over motor symptoms. In addition, comorbidity with neuropsychiatric conditions can act as confounding factors in the diagnostic process.

PD diagnosis is usually straightforward; however, common diagnostic errors can hamper the clinical management of true idiopathic PD cases. The most common diagnostic errors include misdiagnosed cases as dystonic or essential tremor (ET), progressive supranuclear palsy (PSP), multiple systemic atrophy (MSA), dementia with Lewy bodies (DLB), drug induced Parkinsonism, small vessel disease, and psychogenic disorders.
An overview of current diagnostic strategies for movement disorders, such as clinical examinations, blood tests, and neuropsychological evaluations

PD diagnosis is based on information gathered from medical history and detailed neurological examination that focuses on the motor symptoms of the disorder. The United Kingdom PD brain bank criteria are widely used in clinical practice with an estimated specificity of 98.6% and a sensitivity of 91.1% in diagnosing idiopathic PD (Table 1). Nonmotor symptoms of PD are assessed through several questionnaires that can be also used to record PD progression and severity. Depression is amongst the most common nonmotor features in PD affecting approximately 35% of patients. The clinical criteria for depression, as described in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR), the first part of the unified PD rating scale (UPDRS-I), or the Hamilton depression rating scale (HAM-D17) can be used to evaluate depressive disorder in early PD. To the best of our knowledge, the Parkinson’s fatigue scale (PFS-16) is the first rating scale of fatigue based on information acquired from the patients’ perspective.12

The time of dementia onset in PD varies. Cognitive impairment tends to be diagnosed within the first 3–5 years after the diagnosis of PD. The mini mental status examination (MMSE) and the Montreal cognitive assessment (MoCA) questionnaires can nevertheless be used to evaluate cognitive decline in PD. Specifically, MoCA has been suggested to provide higher sensitivity for mild cognitive impairment in early PD than MMSE, while the latter seems to better follow up the progression of cognition problems. Still, both rating scales have not been assessed for their ability to differentiate the diagnosis of dementia in PD from DLB.

Olfactory function is impaired in approximately 90% of PD patients notably at a pre-symptomatic phase around 2–7 years prior to the time that typical motor symptoms appear. Testing of odor discriminating ability with the 40-item University of Pennsylvania identification smell test (UPSIT-40) and the 16-item identification smell test could have potential differential diagnostic value. However, positive results from olfactory testing are apparently not robust enough to suggest idiopathic PD. In addition, olfactory irregularity is not exclusive for PD; it has been also described in patients with PSP, MSA, ET, and Alzheimer’s disease (AD).21

Parasomnias and sleep disorders are amongst the most frequent nonmotor symptoms in PD and can mostly occur as disrupted sleep, sleep behavior disorders (rapid eye movement behavior disorder), sleep apnea, or insomnia.22 The PD sleep scale23 and the Pittsburgh sleep quality index can be used to monitor the state of sleep, possible sleep problems, and their impact on the quality of life.

Several genomic loci have been related with sporadic PD cases, namely, as familial parkinsonian syndromes (familiar PSs) which are directly related to gene mutations. These have been reported to less than 10% of cases diagnosed with PD; of which, PARK8 (Leucine–rich repeat kinase 2, LRRK2, dardarin) and PARK1/PARK4 (α-synuclein, SNCA) have been found to cause autosomal dominant parkinsonism whilst, PARK2 (Parkinson protein 2, E3 ubiquitin protein ligase, PARKIN), PARK6 [phosphatase and tensin homolog (PTEN)–induced putative kinase 1, PINK1] and PARK7 (Parkinson protein 7, protein DJ1, DJ–1) have been identified as responsible for causing autosomal recessive disease. However, sufficient knowledge in order to generate a genomic classification for the vast majority of PD patients and thus determine particular genetic profiles that could impact clinical practice is lacking. Serologic genetic tests are therefore rarely used in routine care for diagnostic purposes unless there is strong evidence of a familiar genetic background where counseling is indicated. Overall, there is no study to our knowledge that focuses on PD diagnosis and compares the strength of these tests against single photon emission computed tomography (SPECT) with 123Iodine-Ioflupane.

Review of chemistry, formulation, and mechanism of action of 123I-Ioflupane injection (DaTscan™)

Neuroimaging techniques, such as magnetic resonance imaging (MRI), transcranial sonography, positron emission tomography (PET), and SPECT can be employed to detect structural and functional changes in vivo and therefore support a PD diagnosis. Specifically, PET and SPECT techniques can be utilized to sensitively detect dopamine terminal loss in unspecified clinical cases of Parkinsonism.

Table 1 UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria: Diagnosis of Parkinsonian syndrome

| Bradykinesia (slowness of initiation or voluntary movement with progressive reduction in speed and amplitude of repetitive actions), and at least one of the following: |
| Muscular rigidity; |
| 4–6 Hz rest tremor; |
| postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction. |

123I-Ioflupane is a SPECT radioligand with high in vivo affinity for dopamine transporter (DAT).\(^{36}\) DAT is a sodium chloride dependent protein in dopaminergic terminals and is responsible for the reuptake of dopamine from the synaptic cleft back to the presynaptic neurons.\(^{37}\) Following the intravenous injection of 123I-Ioflupane, radioactive decay of \(^{123}\)I emits \(\gamma\) radiation. This can be detected externally through a \(\gamma\) camera which records the iodine radioactivity of several DAT-rich subregions of the brain. The main metabolic product of 123I-Ioflupane is FP-CIT acid, a polar compound that is unable to cross the blood-brain barrier. The other metabolites include nor-\(\beta\)-CIT and free iodine. Forty eight hours postinjection, about 60% of the injected radioactivity is excreted in the urine; fecal excretion is estimated to be at approximately 14%.\(^{38}\)

\(\beta\)-Ioflupane (\(\beta\)-FP-CIT) labelled\(^{19,40}\) with \(^{11}\)C or \(^{123}\)I rapidly reaches high concentrations in the human striatum as suggested by autoradiography postmortem in vitro studies in humans, which was also confirmed by striatal accumulation of \(^{11}\)C-\(\beta\)-FP-CIT through PET in vivo imaging in a Cynomolgus monkey.\(^{39}\)

However, 123I-Ioflupane has also been suggested to bind to the serotonin transporter (SERT) in humans.\(^{41}\) This theory was generated following a study in rats that noted high 123I-Ioflupane uptake in the hypothalamus.\(^{42}\) In the same study, acute challenge with vanoxerine (also known as GBR 12,909) administration (which blocks DAT), led to significant reductions in the striatal uptake of 123I-Ioflupane while fluvoxamine (a selective serotonin reuptake inhibitor) did not significantly affect the striatal uptake. On the other hand, fluvoxamine did reduce the uptake of the tracer in the serotonin-rich hypothalamus.\(^{43}\)

### Effectiveness of 123I-Ioflupane in differential diagnosis

123I-Ioflupane has been granted a marketing authorisation by The European Medicines Agency\(^{44}\) valid throughout the European Union in July 2000 (renewed in July 2010) and by the US Food and Drug Administration\(^{45}\) for the United States in January 2011. 123I-Ioflupane is indicated for assessing the loss of functional dopaminergic neuron terminals in the striatum in patients with clinically uncertain PSs which include PSP, MSA, DLB, drug-induced Parkinsonism, and small vessel diseases other than idiopathic PD.

In clinical practice, SPECT with 123I-Ioflupane can be reported as normal or abnormal through subjective visual rating of the 123I-Ioflupane signal. In other words, the examiner must observe SPECT images and judge to what extent the tracer is accumulated in the striatum. This is based on their expertise and knowledge.\(^{46}\) Reduced DAT striatal binding is therefore suggested to depict reduced DAT availability which reflects striatal dopaminergic deficit.

123I-Ioflupane is indicated to discriminate between PSs and ET. In addition, it is indicated to assist in the differential diagnosis between probable DLB and AD. Hence, whereas the main diagnostic question refers to the integrity of the dopaminergic circuit in the striatum, DAT imaging can be utilized to investigate this and differentiate PD, PSP, MSA, or DLB from ET, secondary Parkinsonism, AD, and Huntington’s disease, in which the pathology is not related to dopaminergic depletion in the striatum.\(^{47}\) DAT imaging can therefore

### Table 2 Summarized characteristics of 123I-Ioflupane\(^{35}\)

<table>
<thead>
<tr>
<th>IUPAC name</th>
<th>N-(3-Fluoropropyl)-2β-carbomethoxy-3β-(4-[(^{123})I]iodophenyl)nortropane</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviation</td>
<td>([^{123})I]FP-CIT, ([^{11})C(\beta)-CIT-FP</td>
</tr>
<tr>
<td>Synonyms</td>
<td>123I-Ioflupane, DaTscan™</td>
</tr>
<tr>
<td>Target</td>
<td>DAT ((IC_{50} = 3.5) nM) Serotonin Transporter ((IC_{50} = 9.73) nM)</td>
</tr>
</tbody>
</table>


Abbreviations: DAT, dopamine transporter; \(IC_{50}\), half maximal inhibitory concentration; IUPAC, International Union of Pure and Applied Chemistry.
be particularly useful in the early stages of cases where bradykinesia and rigidity do not manifest as motor symptoms.

In such cases where the tremor is the dominant motor symptom, the diagnosis of either PD or ET is often based on clinical facts without performing DAT imaging. In some of these cases, a misdiagnosed case of ET can actually develop PD. It has been shown that patients with known ET have an approximately four times higher risk in developing PD than controls. In such cases, future imaging studies with 123I-Ioflupane could possibly investigate the prognostic value of DAT imaging.

DP008–003 and PDT–304 studies were open randomized trials for assessing the efficacy of 123I-Ioflupane for DAT binding. The DP008-003 study was designed to estimate the accuracy of 123I-Ioflupane SPECT in confirming known clinical cases of PD against ET and healthy volunteers. PDT-304 was based on the diagnostic value of DAT imaging; in this study, the confirmation was clinical and came afterwards. Both studies were criticized by de la Fuente-Fernández in 2012. The accuracy of 123I-Ioflupane was calculated with a sensitivity of 98% and a specificity of 67% for a possible and probable PD diagnosis in true early PD cases. In already established PD diagnoses, the specificity raises to 94%. However, this ability has not been questioned against neuropathological confirmation. Overall, future comparative studies can clarify this point and increase the accuracy of 123I-Ioflupane in differential diagnoses.

Among PD, PSP, and MSA, the uptake of 123I-Ioflupane has been found to be significantly more reduced in PSP patients than in PD or MSA cases; specifically when using putamen as a region of interest. Of interest, putamen/caudate ratios were calculated in the same study and it was suggested that PSP patients follow a different pattern of dopaminergic degeneration compared to idiopathic PD. Another study suggests that patients with PSs and not PD, eventually show a decrease in dopamine D2 receptors, availability. However, this stemmed from comparisons of imaging data between 123I-Ioflupane and 123I-iodobenzamide (IBZM), which is a radiotracer specific to postsynaptic dopamine D2 receptors. An 123I-IBZM SPECT can be therefore useful only for supporting abnormal imaging with 123I-Ioflupane.

SPECT with 123I-Ioflupane has been employed in a group of patients with corticobasal ganglionic degeneration and showed variable nigrostriatal reductions of the tracer characterized by greater hemispheric asymmetry compared to PD. Despite prominent bilateral disease, about 10% of corticobasal ganglionic degeneration patients of the same series had normal DAT imaging, which may suggest supranigral pathology for corticobasal ganglionic degeneration.

SPECT with 123I-Ioflupane focused on striatal DAT availability is able to differentiate PD from ET with a sensitivity of 95% and a specificity of 93%. Also, idiopathic PD can be differentiated from secondary PD through SPECT with 123I-Ioflupane. However, the diagnostic accuracy of 123I-Ioflupane is suggested to be low between idiopathic PD and atypical PSs. Parkinsonism due to vascular background is sometimes hard to distinguish from true idiopathic PD cases; vascular lesions are often found incidentally in elderly patients in MRI scans. However, a rather symmetrical uptake of striatal 123I-Ioflupane has been suggested to relate to vascular Parkinsonism. Thus, new prospective studies are needed to determine the prognostic value of 123I-Ioflupane for the diagnosis of vascular Parkinsonism.

123I-Ioflupane SPECT for DLB patients has been found to correlate with neuropathological validation of the disorder. Following postmortem analysis in eight patients with DLB compared to nine with AD, SPECT imaging with 123I-Ioflupane almost 10 years before autopsy, was found to have a sensitivity and specificity of 88% and 100% for DLB diagnosis.

123I-Ioflupane can be also employed to differentiate PD from psychogenic Parkinsonism, where nigrostriatal innervation should remain intact. 123I-Ioflupane SPECT data have suggested undamaged dopaminergic nigrostriatal terminals in case studies with psychogenic Parkinsonism.

**Advantages and disadvantages of 123I-Ioflupane**

123I-Ioflupane is used in routine clinical practice through subjective visual rating, a fact that weakens its robustness. However, objectivity may come through a region of interest approach or voxel-based techniques that can enhance its wide clinical use.

From a methodology point of view, images of SPECT with 123I-Ioflupane can be quantified through several methods such as a region of interest (ROI), one-shape analysis of the uptake, Statistical Parametric Mapping (SPM) analysis based on ROI/background ratios, and principal component analysis. Others are based on the machine learning paradigm that can be applied to the SPECT images through computer-aided diagnosis systems that can assist the diagnosis of PSs. An interesting method for quantitative measure of uptake has been proposed to assist the diagnosis of uncertain PSs and possibly measure disease progression. This method combines principal components analysis and provides an automatic
classification as PS or nonPS with an accuracy measured at approximately 94.8%. Further to this work, another group proposed an improved automatic computer-aided diagnosis system with similar results (accuracy of approximately 94%). Hence, image quantification can provide objectivity in order to avoid incorrect qualification for bilateral symmetric reduction sometimes found in MSA or PSP.

123I-Ioflupane has been proven to increase the diagnostic confidence for uncertain Parkinsonian cases when they clinically resemble idiopathic PD. When the clinical evaluation is not clear and there is a need for assessing in vivo the striatal dopaminergic deficit in movement disorders, SPECT with 123I-Ioflupane is indicated to support the clinical diagnosis. Less diagnostic errors enhance good clinical practice and reduce further costs and inappropriate anti-Parkinsonian treatment.

A recent study collected 1701 123I-FP-CIT SPECT scans of patients with uncertain clinical PSs. A cost-effectiveness analysis model was applied in this registry and it was shown that DAT imaging is influential in the diagnosis and further pharmacological management of patients with uncertain PSs. To this point, another study has proposed potential cost savings in treatment of PD. However, future cost-effectiveness studies should focus on the prognostic value of SPECT imaging with 123I-FP-CIT SPECT in order to avoid management errors and side effects that increase treatment costs. Moreover, the cost of SPECT imaging is much less compared to other functional imaging techniques such as PET. Overall, it is a safe and well tolerated investigation.

**Conclusion**

123I-Ioflupane is a powerful and widely used SPECT radiotracer for assisting differential diagnosis in PSs where the pathology refers to a striatal dopaminergic deficit. A pathological confirmation from postmortem data following SPECT imaging with 123I-Ioflupane is sine qua non for estimating the accuracy and the prognostic value of this compound. SPECT with 123I-Ioflupane can also be used to monitor treatment assessing several dopaminergic medications.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

Degenerative Neurological and Neuromuscular Disease 2013:3


